NASDAQ: PXMDPaxmedica Inc Stock
$0.75-0.01 (-1.32%)
Updated Apr 22, 2024
PXMD Price
$0.75
Fair Value Price
N/A
Market Cap
$5.57M
52 Week Low
$0.37
52 Week High
$29.75
P/E
-0.07x
P/B
1.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$18.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.68
Operating Cash Flow
-$11M
Beta
0.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PXMD Overview
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PXMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PXMD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PXMD is good value based on its book value relative to its share price (1.65x), compared to the US Biotechnology industry average (5.82x)
P/B vs Industry Valuation
PXMD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PXMD due diligence checks available for Premium users.
Be the first to know about important PXMD news, forecast changes, insider trades & much more!
PXMD News
Valuation
PXMD fair value
Fair Value of PXMD stock based on Discounted Cash Flow (DCF)
Price
$0.75
Fair Value
$0.20
Overvalued by
279.34%
PXMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PXMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
16.21x
Market
41x
PXMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.65x
Industry
5.82x
PXMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PXMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.9M
Profit Margin
0%
PXMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$5.7M
Liabilities
$2.3M
Debt to equity
0.68
PXMD's short-term assets ($5.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PXMD's short-term assets ($5.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PXMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PXMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.6M
Investing
$0.0
Financing
$6.2M
PXMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PXMD vs Biotech Stocks
Paxmedica Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.